<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136292</url>
  </required_header>
  <id_info>
    <org_study_id>3009-028</org_study_id>
    <secondary_id>DAP-PEDS-05-01</secondary_id>
    <nct_id>NCT00136292</nct_id>
  </id_info>
  <brief_title>Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics</brief_title>
  <official_title>An Evaluation of the Pharmacokinetics of a Single Dose of Daptomycin (4 mg/kg) in Pediatric Patients Aged Two to Seventeen Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin&#xD;
      in patients aged 2-17 years old who have a suspected or proven gram-positive infection for&#xD;
      which they are receiving standard antibiotic therapy. The tolerability of a single dose of&#xD;
      daptomycin in these patients will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2005</start_date>
  <completion_date type="Actual">August 9, 2006</completion_date>
  <primary_completion_date type="Actual">August 1, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Gram-positive Bacterial Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daptomycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  2-17 years old&#xD;
&#xD;
          -  Suspected or diagnosed gram-positive infection for which the patient is receiving&#xD;
             standard antibiotic therapy&#xD;
&#xD;
          -  Clinically stable with no evidence of hemodynamic instability in the 72 hour window&#xD;
             prior to enrollment, and no history or evidence of renal or hepatic compromise, or&#xD;
             clinically significant alterations in fluid/electrolyte homeostasis&#xD;
&#xD;
          -  Creatinine clearance (CLcr) â‰¥ 80 ml/min/1.73 m2 as determined by the Schwartz equation&#xD;
&#xD;
          -  Creatine phosphokinase (CPK) levels within normal limits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to daptomycin&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, pulmonary&#xD;
             (well-controlled asthma is acceptable), gastrointestinal, endocrine, hematologic, or&#xD;
             autoimmune disease&#xD;
&#xD;
          -  Pneumonia as sole gram-positive infection&#xD;
&#xD;
          -  Use of HMG-CoA reductase inhibitors or other systemic anti-hyperlipidemic agents&#xD;
             within 7 days prior to study drug administration and expected use through 3 days&#xD;
             post-dose&#xD;
&#xD;
          -  Clinically significant abnormal laboratory test results (including electrocardiograms&#xD;
             [ECGs]), as determined by Investigator&#xD;
&#xD;
          -  Body mass index (BMI) that is outside of the 5th to 95th percentile for age&#xD;
&#xD;
          -  History (personal or 1st degree relative) of clinically significant muscular disease,&#xD;
             nervous system, seizure or psychiatric disorder&#xD;
&#xD;
          -  Expected intramuscular (IM) injection within 3 days following dosing&#xD;
&#xD;
          -  Expected surgical procedure(s) within 3 days following dosing&#xD;
&#xD;
          -  Unexplained muscular weakness&#xD;
&#xD;
          -  Rhabdomyolysis, myositis or septic shock&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Jacobs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Abdel-Rahman SM, Benziger DP, Jacobs RF, Jafri HS, Hong EF, Kearns GL. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J. 2008 Apr;27(4):330-4. doi: 10.1097/INF.0b013e318160edfc.</citation>
    <PMID>18316988</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram-Positive Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

